Loading…
Ligand Pharmaceuticals Incorporated is projected to rise to $447.14 by 2027, a +51% move from its current price of $296.29. LGND is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $290.96 | $296.51 | $302.17 | +0.08% |
| Aug 2 | $288.91 | $296.74 | $304.78 | +0.15% |
| Aug 3 | $287.40 | $296.96 | $306.84 | +0.23% |
| Aug 4 | $286.16 | $297.19 | $308.64 | +0.30% |
| Aug 5 | $285.10 | $297.41 | $310.25 | +0.38% |
| Aug 6 | $284.17 | $297.64 | $311.74 | +0.45% |
| Aug 7 | $283.33 | $297.86 | $313.13 | +0.53% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $283.33 | $297.86 | $313.13 | +0.53% |
| Week 2 | $279.00 | $299.44 | $321.38 | +1.06% |
| Week 3 | $276.05 | $301.03 | $328.26 | +1.60% |
| Week 4 | $273.83 | $302.63 | $334.46 | +2.14% |
| Week 5 | $272.05 | $304.23 | $340.22 | +2.68% |
| Week 6 | $270.59 | $305.85 | $345.70 | +3.23% |
| Week 7 | $269.37 | $307.47 | $350.96 | +3.77% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that develops and licenses biopharmaceutical assets worldwide. Its portfolio spans infectious disease, oncology, nephrology, neurology and other areas, with products including Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin A nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes.
In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; Reproxalap for opthamology; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.
Ligand Pharmaceuticals is trading at $296.26 with a market cap of $5.94B and a rank of 1266. The price outlook is reflected in the year-by-year forecast, with 2026 showing a min of $181.65, an avg of $296.26 and a max of $417.73, ROI 0, and sentiment NEUTRAL. From 2027 onward the avg price climbs to $445.64 (ROI 50.4%) and higher, reaching $717.66 by 2030 (ROI 142.2%), $2,734.22 by 2040 (ROI 822.9%), and $5,934.58 by 2050 (ROI 1903.2%), with a BULLISH sentiment in most years.
A major floor 35.0% below — a decisive break under it would weaken the trend.
The nearest floor, 11.5% below — buyers have tended to step in here.
The nearest ceiling, 8.9% above — a clean break opens room to run.
A major ceiling 19.5% above — clearing it would confirm fresh momentum.
Key LGND support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of LGND market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $295.72 | Buy | $295.66 | Buy |
| MA 10 | $298.79 | Sell | $298.03 | Sell |
| MA 20 | $305.20 | Sell | $297.43 | Sell |
| MA 50 | $274.85 | Buy | $279.27 | Buy |
| MA 100 | $245.23 | Buy | $254.85 | Buy |
| MA 200 | $219.70 | Buy | $224.55 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 51.71 | Neutral |
| Stoch RSI (14) | 31.47 | Neutral |
| CCI (20) | -68.82 | Neutral |
| Williams %R (14) | -61.02 | Info |
| MACD (12,26,9) | -3.78 | Sell |
| ROC (12) | -1.55 | Sell |
| Bollinger %B (20,2) | 0.28 | Neutral |
| Stochastic %K (14) | 38.98 | Neutral |
| TRIX (15) | 0.42 | Buy |
| Awesome (5,34) | 0.76 | Buy |
| Ultimate (7,14,28) | 36.83 | Neutral |
| Momentum (10) | -0.16 | Sell |
| Aroon Osc (25) | 40.00 | Buy |
| Hull MA (9) | 291.51 | Buy |
| ADX (14) | 22.79 | Buy |
| ATR (14) | 5.33 | Info |
The 30-day technical picture shows bullish momentum, with RSI(14) at 50. The 50-day simple moving average sits at $257.74, above the 200-day SMA of $213.13, suggesting constructive near-term momentum. Current support is at $232.76 and resistance at $322.61.
The latest 30-day range has traded between $259.34 and $338.43, and the stock exhibits an annualized volatility of 40, indicating notable near-term variability.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $181.65 | $296.29 | $407.68 | 0% | Neutral | |
| $366.56 | $447.14 | $570.01 | +51% | Bullish | |
| $416.26 | $517.47 | $677.84 | +75% | Bullish | |
| $482.99 | $609.79 | $816.01 | +106% | Bullish | |
| $568.64 | $727.72 | $991.54 | +146% | Bullish | |
| $612.79 | $793.89 | $1,098.94 | +168% | Bullish | |
| $796.17 | $1,043.19 | $1,464.74 | +252% | Bullish | |
| $984.25 | $1,303.30 | $1,853.82 | +340% | Bullish | |
| $1,030.70 | $1,378.48 | $1,984.34 | +365% | Bullish | |
| $1,140.61 | $1,540.00 | $2,241.67 | +420% | Bullish | |
| $1,977.82 | $2,785.80 | $4,250.57 | +840% | Bullish | |
| $3,956.46 | $5,978.78 | $9,781.28 | +19.2x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $181.65 | $296.29 | $345.02 | +0.00% |
| August 2026 | $259.46 | $302.55 | $359.55 | +2.11% |
| September 2026 | $270.67 | $317.43 | $380.79 | +4.92% |
| October 2026 | $276.81 | $326.14 | $394.15 | +2.74% |
| November 2026 | $275.58 | $325.91 | $396.26 | -0.07% |
| December 2026 | $281.02 | $333.49 | $407.68 | +2.32% |
Click any year to see its month-by-month LGND forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Ligand Pharmaceuticals Incorporated's 2026 outlook centres on $296.29, within a $181.65 to $407.68 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, LGND could reach as high as $570.01, with a base case around $447.14 and support toward $366.56 — roughly +51% from $296.29. Buyers look set to stay in control over this stretch.
Expect LGND to range from $416.26 to $677.84 through 2028. The $517.47 average target implies a +75% move from current prices. That is up +16% on the projected 2027 average. Momentum favours further upside here.
The LGND price prediction for 2029 points to an average of $609.79 (low $482.99, high $816.01) — a potential gain of +106% on today's $296.29. Buyers look set to stay in control over this stretch.
In 2030, LGND is projected to trade between $568.64 and $991.54, averaging $727.72 — a potential gain of +146% from today's $296.29. That is up +19% on the projected 2029 average. Momentum favours further upside here.
Ligand Pharmaceuticals Incorporated's 2031 outlook centres on $793.89, within a $612.79 to $1,098.94 range. That is up +9% on the projected 2030 average. That marks a +168% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, LGND could reach as high as $1,464.74, with a base case around $1,043.19 and support toward $796.17 — roughly +252% from $296.29. Momentum favours further upside here.
Expect LGND to range from $984.25 to $1,853.82 through 2033. The $1,303.30 average target implies a +340% move from current prices. That is up +25% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The LGND price prediction for 2034 points to an average of $1,378.48 (low $1,030.70, high $1,984.34) — a potential gain of +365% on today's $296.29. Momentum favours further upside here.
In 2035, LGND is projected to trade between $1,140.61 and $2,241.67, averaging $1,540.00 — a potential gain of +420% from today's $296.29. That is up +12% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Ligand Pharmaceuticals Incorporated's 2040 outlook centres on $2,785.80, within a $1,977.82 to $4,250.57 range. That is up +81% on the projected 2035 average. That marks a +840% change versus current levels. Momentum favours further upside here.
By 2050, LGND could reach as high as $9,781.28, with a base case around $5,978.78 and support toward $3,956.46 — roughly +19.2x from $296.29. Buyers look set to stay in control over this stretch.
Investing $1,000 in LGND today (≈ 3.375072 LGND) could be worth
$20,178.82
+$19,178.82 (+1918%) by 2050 · US Dollar
Based on the average projected LGND price of $5,978.78 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in LGNDwould be worth at today's price.
$1,000 invested in LGND on Jul 30, 2025 (≈ 7.394809 LGND) would be worth
$2,191.01
+$1,191.01 (+119.1%) today · 2.19× · US Dollar
Based on a LGND entry price of $135.23 vs. today's $296.29.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $302.15 | $980.61 | -1.9% |
| 1 month ago | $316.09 | $937.36 | -6.3% |
| 3 months ago | $227.44 | $1,302.72 | +30.3% |
| 6 months ago | $192.1 | $1,542.37 | +54.2% |
| 1 year ago | $135.23 | $2,191.01 | +119.1% |
| All time (5.0y) ago | $69.21 | $4,280.78 | +328.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our LGND forecast.
Our base-case forecast reaches $590.00 around 2029.
Implied market cap at $590.00: $11.82B
The multi-year forecast depicts a bullish trajectory for LGND. The 2026 average price is $296.26 with ROI 0 and sentiment NEUTRAL. The 2030 average is $717.66 with ROI 142.2 and bullish sentiment, while the 2040 average is $2,734.22 with ROI 822.9.
By 2050, the average is $5,934.58 with ROI 1903.2. The forecast also shows potential upside in later years, with a 2040 max of $4,241.66 and a 2050 max of $9,904.32. These are estimates and not guarantees, and they carry inherent uncertainties given market conditions and other factors.
Tap a question to reveal the answer.
2030: min $556.12, avg $717.66, max $988.48; ROI 142.2; sentiment BULLISH.
The forecast includes neutral in 2026 (avg $296.26, ROI 0) and bullish in 2027 onward, with rising averages through 2050, but these are estimates and not guarantees.
2030 max is $988.48; 2032 max $1,499.06, so it could exceed $1,000 by 2032.
Current price $296.26.
2040: min $1,910.67, avg $2,734.22, max $4,241.66; ROI 822.9; sentiment BULLISH.
Ligand Pharmaceuticals Incorporated Community Discussion
0Share your Ligand Pharmaceuticals Incorporated price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.